Fish Oil — Research Profile

What the Research Says

Fish oil is a well-researched nutritional supplement with substantial evidence supporting its cardiovascular benefits. The REDUCE-IT trial (Bhatt et al., 2019) demonstrated that 4g of icosapent ethyl, a purified form of EPA, reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides. A Cochrane review by Abdelhamid et al. (2020) confirmed omega-3 fatty acids effectively lower triglycerides and may reduce coronary heart disease events and mortality, though effects on total mortality were less clear.

Beyond cardiovascular health, fish oil has shown efficacy in mental health. Liao et al. (2019) meta-analyzed 26 RCTs, finding significant antidepressant benefits, particularly with EPA-dominant formulations at doses exceeding 1g/day. Anti-inflammatory mechanisms of omega-3 fatty acids were elucidated by Calder (2017), who explained that EPA and DHA compete with arachidonic acid for COX-2/LOX enzymes, generating specialized pro-resolving mediators that actively resolve inflammation.

Recent studies highlight additional benefits. Zhou et al. (2022) found fish oil supplementation significantly reduced CRP levels in hemodialysis patients, particularly in those with elevated baseline CRP. Khoshnoudi-Nia et al. (2022) reviewed encapsulation methods, identifying electrohydrodynamic techniques as highly efficient for fish oil delivery using polysaccharide-protein walls. These findings underscore the versatility and continued relevance of fish oil research across diverse health applications.

Fish oil has also been studied in specific populations. Rajati et al. (2024) conducted a systematic review and meta-analysis of 16 studies, finding that omega-3 supplementation and fish oil significantly reduced the risk of total preeclampsia (RR: 0.63; P=0.027) and severe preeclampsia (RR: 0.45; P=0.011). Pradelli et al. (2025) found that fish oil parenteral nutrition (FO-PN) reduces infection risk in hospitalized non-ICU patients, based on a systematic review/meta-analysis of 29 RCTs.

In summary, fish oil has demonstrated cardiovascular benefits, anti-inflammatory effects, and potential applications in mental health and specific populations. Continued research underscores its versatility and relevance across diverse

Benefits of Fish Oil

• Cardiovascular event reduction — The REDUCE-IT trial (Bhatt et al., 2019) randomized 8,179 statin-treated patients with elevated triglycerides to 4g icosapent ethyl (high-purity EPA) or placebo; EPA reduced major adverse cardiovascular events by 25%, ischemic events by 26%, and cardiovascular death by 20%, establishing high-dose EPA as a prescription-grade cardiovascular intervention
• Triglyceride reduction — A Cochrane meta-analysis by Abdelhamid et al. (2020) confirmed that omega-3 supplementation reliably reduces triglycerides by 15-30% at standard doses (2-4g EPA+DHA), with effects dose-dependent and most pronounced in hypertriglyceridemic patients; this is the most robust and reproducible effect of fish oil supplementation
• Depression and mood improvement — Liao et al. (2019) published a meta-analysis of 26 RCTs showing omega-3 supplementation significantly improved depressive symptoms compared to placebo, with EPA-predominant formulations (≥60% EPA) showing the largest effect sizes; DHA-predominant formulations were less effective for depression specifically
• Anti-inflammatory effects — Calder (2017) reviewed the mechanisms by which EPA and DHA reduce inflammation: they compete with arachidonic acid for COX-2 and LOX enzymes, reduce pro-inflammatory prostaglandins and leukotrienes, and generate specialized pro-resolving mediators (resolvins and protectins) that actively resolve inflammation rather than merely suppressing it
• Joint pain and arthritis relief — Goldberg & Katz (2007) meta-analyzed 17 RCTs and found that omega-3 supplementation significantly reduced joint pain intensity and morning stiffness in patients with rheumatoid arthritis and inflammatory joint disease, with some patients able to reduce NSAID use

Side Effects and Safety

Safety profile: Generally Safe

Potential Side Effects

• Fishy burps and aftertaste — the most common complaint; reduced by enteric-coated capsules, triglyceride-form oil, refrigeration, or taking with meals
• GI discomfort (nausea, diarrhea, bloating) — dose-dependent; start at 1g and increase gradually
• Increased bleeding time — clinically insignificant at doses under 3g; relevant at high doses or with anticoagulants
• Mild fishy body odor at high doses — uncommon but reported; may indicate oxidized (rancid) product
• LDL cholesterol increase at very high doses — high-dose DHA (>2g) may modestly raise LDL in some individuals; EPA-only formulations avoid this

Drug & Supplement Interactions

• Anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel, heparin) — omega-3s have antiplatelet effects; additive bleeding risk at high doses
• Antihypertensive medications — fish oil may lower blood pressure by 2-5 mmHg; monitor for additive hypotension
• Orlistat — blocks fat absorption, reducing fish oil uptake; separate doses by 2+ hours
• Statin medications — fish oil complements statins for triglyceride reduction (REDUCE-IT used fish oil + statin); no negative interaction
• Cyclosporine — fish oil may alter cyclosporine levels; monitor in transplant patients